July 2026
Added to Dediabetes Jul 12, 2026RCTs
This study evaluated the effects of extra virgin olive oil supplementation in women with gestational diabetes, finding significant reductions in insulin requirements and neonatal complications.
Interventions
Extra virgin olive oil supplementation
Outcomes
BMIGestational age at delivery (weeks)Gestational weight gain+4 more
Added to Dediabetes Jul 12, 2026RCTs
EWP supplementation improved nutritional status and reduced oxidative stress in diabetic hemodialysis patients.
Interventions
Egg White Powder (EWP)
Outcomes
Fasting Plasma Glucose (FPG)LDL cholesterolMalondialdehyde (MDA)+5 more
Added to Dediabetes Jul 12, 2026RCTs
This study investigated the impact of a regular exercise program on sleep habits in children with Type 1 Diabetes, revealing significant improvements in various sleep-related outcomes.
Interventions
Aerobic exercise
Outcomes
Average sleep habits score measured by the Children's Sleep Habits QuestionnaireBedtime resistanceNight wakings score+6 more
Added to Dediabetes Jul 12, 2026RCTs
A comprehensive exercise program significantly improved sleep quality and various health markers in adults with type 2 diabetes.
Interventions
Aerobic exercise
Outcomes
BMIBlood glucoseHbA1c+8 more
Added to Dediabetes Jul 12, 2026RCTs
A family-oriented mHealth intervention including 24 videos on T2D self-management and behavioral techniques.
Interventions
mHealth intervention with personal feedback
Outcomes
Body weightDiabetes self-management behaviorsHbA1c+2 more
Added to Dediabetes Jul 12, 2026RCTs
This study compared Family-DSMES and Standard-DSMES in participants with diabetes, finding significant improvements in diabetes-related family involvement with Family-DSMES.
Outcomes
HbA1cImprovement in diabetes-related helpful family involvement
Added to Dediabetes Jul 12, 2026RCTs
The Finerenone Trial investigated the efficacy and safety of finerenone compared to placebo in patients with heart failure, demonstrating significant benefits.
Interventions
Finerenone (nonsteroidal mineralocorticoid receptor antagonist)
Outcomes
Cardiovascular deathHospitalization for heart failureTotal worsening heart failure events and death from cardiovascular causes
Added to Dediabetes Jul 12, 2026RCTs
The FIGARO-DKD trial subgroup analysis evaluated finerenone in patients with type 2 diabetes and chronic kidney disease, finding significant reductions in kidney failure risk.
Interventions
Finerenone (nonsteroidal mineralocorticoid receptor antagonist)
Outcomes
Incidence of hyperkalemiaTime to cardiovascular deathTime to kidney failure, sustained eGFR decline ≥40% from baseline, or kidney-related death
Added to Dediabetes Jul 12, 2026RCTs
This study evaluated the effects of finerenone on heart and kidney events in patients with chronic kidney disease and type 2 diabetes, finding significant reductions in event rates compared to placebo.
Interventions
Finerenone (nonsteroidal mineralocorticoid receptor antagonist)
Outcomes
Adverse events incidenceComposite cardiovascular events (CV death, MI, stroke, HF hospitalization)Composite cardiovascular outcome+4 more
Added to Dediabetes Jul 12, 2026RCTs
The study evaluated the effect of Finerenone on hypokalaemia in patients with chronic kidney disease and type 2 diabetes, finding a significant reduction in incidence compared to placebo.
Interventions
Finerenone (nonsteroidal mineralocorticoid receptor antagonist)
Outcomes
Arrhythmia composite outcomeComposite cardiovascular events (CV death, MI, stroke, HF hospitalization)Hypokalaemia incidence